In group plans, the relevant question is whether GLP-1 coverage is structured around diabetes only, weight loss only, or both. A 2026 survey by the International Foundation of Employee Benefit Plans (IFEBP) of nearly 300 US health plans found that 60% of employers cover GLP-1 drugs for diabetes only, up from 55% in 2025. Just 36% cover them for both diabetes and weight loss, unchanged year over year. GLP-1 drugs now account for 11.4% of annual claims among employers that cover them for weight loss, up from 6.9% in 2023.
Disclaimer: This story is auto-aggregated by a computer program and has not been created or edited by finopulse.
Publisher: Source link
